Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0015695 (
fatty liver
)
13,941
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The liver integrates multiple metabolic pathways to warrant systemic energy homeostasis. An excessive lipogenic flux due to chronic dietary stimulation contributes to the development of
hepatic steatosis
, dyslipidemia and hyperglycemia. Here we show that the oxidoreductase
retinol saturase
(
RetSat
) is involved in the development of
fatty liver
. Hepatic
RetSat
expression correlates with steatosis and serum triglycerides (TGs) in humans. Liver-specific depletion of
RetSat
in dietary obese mice lowers hepatic and circulating TGs and normalizes hyperglycemia. Mechanistically,
RetSat
depletion reduces the activity of carbohydrate response element binding protein (ChREBP), a cellular hexose-phosphate sensor and inducer of lipogenesis. Defects upon
RetSat
depletion are rescued by ectopic expression of ChREBP but not by its putative enzymatic product 13,14-dihydroretinol, suggesting that
RetSat
affects hepatic glucose sensing independent of retinol conversion. Thus,
RetSat
is a critical regulator of liver metabolism functioning upstream of ChREBP. Pharmacological inhibition of liver
RetSat
may represent a therapeutic approach for steatosis.
Fatty liver
is one of the major features of metabolic syndrome and its development is associated with deregulation of systemic lipid and glucose homeostasis. Here Heidenreich et al. show that
retinol saturase
is implicated in hepatic lipid metabolism by regulating the activity of the transcription factor ChREBP.
...
PMID:Retinol saturase coordinates liver metabolism by regulating ChREBP activity. 2885